Download - Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Transcript
Page 1: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 2: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 3: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 4: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 5: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 6: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 7: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 8: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 9: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 10: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 11: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 12: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 13: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 14: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 15: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 16: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 17: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 18: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 19: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 20: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 21: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 22: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 23: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 24: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 25: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 26: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 27: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 28: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 29: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 30: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 31: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 32: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 33: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 34: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 35: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 36: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 37: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 38: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 39: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 40: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 41: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 42: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 43: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 44: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 45: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 46: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 47: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 48: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 49: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 50: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 51: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 52: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 53: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 54: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 55: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 56: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 57: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 58: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Top Related

Biological evaluation of a novel sorafenib analogue, t‑CUPMAbstract Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular

Biological evaluation of a novel sorafenib analogue, t‑CUPMAbstract Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular

Differential Effects of Sorafenib on Liver Versus Tumor ...

Differential Effects of Sorafenib on Liver Versus Tumor ...

Theranostics · Web viewAll these 119 patients received mono sorafenib therapy or systemic therapy containing sorafenib; according to NCCN guidelines for advanced hepatobiliary cancers

Theranostics · Web viewAll these 119 patients received mono sorafenib therapy or systemic therapy containing sorafenib; according to NCCN guidelines for advanced hepatobiliary cancers

Lenvatinib and sorafenib for treating differentiated ...

Lenvatinib and sorafenib for treating differentiated ...

FORMULATION AND EVALUATION OF SORAFENIB TOSYLATE …repository-tnmgrmu.ac.in/3365/1/2601076chansulthanasm.pdf · 8.7 DSC Thermal analysis of Sorafenib tosylate with SLS 89 8.8 DSC

FORMULATION AND EVALUATION OF SORAFENIB TOSYLATE …repository-tnmgrmu.ac.in/3365/1/2601076chansulthanasm.pdf · 8.7 DSC Thermal analysis of Sorafenib tosylate with SLS 89 8.8 DSC

Sorafenib and HCC: Is It All About VEGF?

Sorafenib and HCC: Is It All About VEGF?

OSU-2S/Sorafenib Synergistic Antitumor Combination against ... · Background: Sorafenib (Nexavar R) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC).

OSU-2S/Sorafenib Synergistic Antitumor Combination against ... · Background: Sorafenib (Nexavar R) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC).

Intermediate stage HCC treatment options: TACE + sorafenib.

Intermediate stage HCC treatment options: TACE + sorafenib.

Languages
Pages
Legal

Copyright © 2022 FDOCUMENTS